Want to see PROK full AI Analyst Report?
Top Page
ProKidney
(NASDAQ:PROK)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▲(15.61% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by very weak financial performance (minimal revenue, large losses, and substantial cash burn implying continued financing needs). Technicals are mixed—some near-term stabilization but still below key longer-term moving averages. Corporate updates around Phase 3 progress and regulatory alignment provide a positive offset, while valuation remains unattractive on a negative P/E.
Positive Factors
Focused Cell Therapy Pipeline
A focused lead program addresses a defined chronic disease population and is designed to preserve kidney function rather than merely treat symptoms. If clinical development succeeds, this differentiated cell-therapy approach could support a durable commercial opportunity in a serious, ongoing condition.
Negative Factors
Minimal and Declining Revenue
Minimal, volatile revenue confirms that the company has not yet established a meaningful commercial revenue base. With current sales unable to support operations, the investment case remains dependent on successful clinical development, regulatory approval, and future commercialization of rilparencel.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Cell Therapy Pipeline
A focused lead program addresses a defined chronic disease population and is designed to preserve kidney function rather than merely treat symptoms. If clinical development succeeds, this differentiated cell-therapy approach could support a durable commercial opportunity in a serious, ongoing condition.
Read all positive factors
ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$544.18M
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)2.19
Revenue Growth55.22%
EPS Growth2.13%
CountryUS
Employees231
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding208,926,940
10 Day Avg. Volume919,244
30 Day Avg. Volume1,054,486
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.75Price Target Upside232.37% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$485.71K
ProKidney Business Overview & Revenue Model
Company Description
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derive...
How the Company Makes Money
As a clinical-stage biotechnology company, ProKidney does not have publicly established, recurring product sales revenue from approved therapies; therefore, revenue is primarily expected to come in the future if its lead candidate (rilparencel/REA...
ProKidney Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 818.00K | 893.00K | 76.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.07M | 893.00K | 76.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -160.75M | -144.62M | -158.49M | -125.59M | -143.99M | -53.12M |
| Net Income | -86.71M | -68.99M | -61.19M | -35.47M | -108.03M | -55.15M |
Balance Sheet | ||||||
| Total Assets | 249.02M | 335.57M | 441.07M | 420.55M | 518.00M | 40.30M |
| Cash, Cash Equivalents and Short-Term Investments | 181.56M | 270.02M | 358.29M | 362.95M | 490.25M | 20.56M |
| Total Debt | 3.52M | 4.04M | 3.24M | 4.41M | 2.40M | 1.33M |
| Total Liabilities | 26.18M | 34.78M | 39.44M | 29.22M | 13.06M | 13.38M |
| Stockholders Equity | -883.53M | -1.01B | -994.95M | -1.10B | -1.10B | 26.92M |
Cash Flow | ||||||
| Free Cash Flow | -159.73M | -135.31M | -155.86M | -124.27M | -78.94M | -55.49M |
| Operating Cash Flow | -141.17M | -120.12M | -126.35M | -90.07M | -77.09M | -50.30M |
| Investing Cash Flow | 104.74M | 103.97M | 20.41M | -329.98M | -1.74M | -5.19M |
| Financing Cash Flow | 26.35M | 25.57M | 144.41M | -9.55M | 548.52M | 71.47M |
ProKidney Technical Analysis
Neutral
1.73
Price Trends
1.67
Positive
1.74
Positive
1.94
Negative
Market Momentum
0.08
Negative
53.47
Neutral
24.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Neutral. The current price of 1.73 is above the 20-day moving average (MA) of 1.72, above the 50-day MA of 1.67, and below the 200-day MA of 1.94, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 53.47 is Neutral, neither overbought nor oversold. The STOCH value of 24.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PROK.
ProKidney Risk Analysis
ProKidney disclosed 92 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProKidney Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $2.60B | -7.28 | -76.09% | ― | -58.40% | -31.99% | |
56 Neutral | $406.35M | -5.15 | -58.82% | ― | ― | 29.97% | |
55 Neutral | $2.07B | -21.37 | 81.78% | ― | 100.27% | 39.90% | |
53 Neutral | $4.14B | -12.02 | -42.27% | ― | 23.86% | 19.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $676.33M | -6.53 | 25.70% | ― | 110.16% | 73.04% | |
45 Neutral | $544.18M | -3.16 | 8.83% | ― | 55.22% | 2.13% |
* Healthcare Sector Average
PROK
ProKidney
1.80
-0.65
-26.53%
RZLT
Rezolute
4.22
-3.25
-43.51%
URGN
Urogen Pharma
42.31
24.25
134.27%
PHAT
Phathom Pharmaceuticals
8.36
-3.12
-27.18%
RLAY
Relay Therapeutics
18.87
14.81
364.78%
NRIX
Nurix Therapeutics
25.10
16.43
189.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.